Literature DB >> 31757809

The lipid membrane of HIV-1 stabilizes the viral envelope glycoproteins and modulates their sensitivity to antibody neutralization.

Hamid Salimi1, Jacklyn Johnson1, Manuel G Flores1, Michael S Zhang1, Yunxia O'Malley1, Jon C Houtman1, Patrick M Schlievert1, Hillel Haim2.   

Abstract

The envelope glycoproteins (Envs) of HIV-1 are embedded in the cholesterol-rich lipid membrane of the virus. Chemical depletion of cholesterol from HIV-1 particles inactivates their infectivity. We observed that diverse HIV-1 strains exhibit a range of sensitivities to such treatment. Differences in sensitivity to cholesterol depletion could not be explained by variation in Env components known to interact with cholesterol, including the cholesterol-recognition motif and cytoplasmic tail of gp41. Using antibody-binding assays, measurements of virus infectivity, and analyses of lipid membrane order, we found that depletion of cholesterol from HIV-1 particles decreases the conformational stability of Env. It enhances exposure of partially cryptic epitopes on the trimer and increases sensitivity to structure-perturbing treatments such as antibodies and cold denaturation. Substitutions in the cholesterol-interacting motif of gp41 induced similar effects as depletion of cholesterol. Surface-acting agents, which are incorporated into the virus lipid membrane, caused similar effects as disruption of the Env-cholesterol interaction. Furthermore, substitutions in gp120 that increased structural stability of Env (i.e. induced a "closed" conformation of the trimer) increased virus resistance to cholesterol depletion and to the surface-acting agents. Collectively, these results indicate a critical contribution of the viral membrane to the stability of the Env trimer and to neutralization resistance against antibodies. Our findings suggest that the potency of poorly neutralizing antibodies, which are commonly elicited in vaccinated individuals, may be markedly enhanced by altering the lipid composition of the viral membrane.
© 2020 Salimi et al.

Entities:  

Keywords:  antibody; cholesterol; envelope glycoproteins; human immunodeficiency virus (HIV); lipid raft; membrane lipid; protein conformation; protein stability; surface-acting agent; vaccine development; virus entry

Mesh:

Substances:

Year:  2019        PMID: 31757809      PMCID: PMC6956520          DOI: 10.1074/jbc.RA119.009481

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  113 in total

Review 1.  Revitalizing membrane rafts: new tools and insights.

Authors:  Kai Simons; Mathias J Gerl
Journal:  Nat Rev Mol Cell Biol       Date:  2010-10       Impact factor: 94.444

2.  Juxtamembrane protein segments that contribute to recruitment of cholesterol into domains.

Authors:  Raquel F Epand; Annick Thomas; Robert Brasseur; Sundaram A Vishwanathan; Eric Hunter; Richard M Epand
Journal:  Biochemistry       Date:  2006-05-16       Impact factor: 3.162

Review 3.  Dissipative dynamics of fluid lipid membranes enriched in cholesterol.

Authors:  Laura R Arriaga; Ruddi Rodríguez-García; Lara H Moleiro; Sylvain Prévost; Iván López-Montero; Thomas Hellweg; Francisco Monroy
Journal:  Adv Colloid Interface Sci       Date:  2017-07-18       Impact factor: 12.984

Review 4.  HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation.

Authors:  Mary Ann Checkley; Benjamin G Luttge; Eric O Freed
Journal:  J Mol Biol       Date:  2011-07-22       Impact factor: 5.469

Review 5.  The tale of the long tail: the cytoplasmic domain of HIV-1 gp41.

Authors:  Thomas S Postler; Ronald C Desrosiers
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

6.  Peripheral-type benzodiazepine receptor function in cholesterol transport. Identification of a putative cholesterol recognition/interaction amino acid sequence and consensus pattern.

Authors:  H Li; V Papadopoulos
Journal:  Endocrinology       Date:  1998-12       Impact factor: 4.736

7.  Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1.

Authors:  A Trkola; M Purtscher; T Muster; C Ballaun; A Buchacher; N Sullivan; K Srinivasan; J Sodroski; J P Moore; H Katinger
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

Review 8.  Progress and Perspectives on HIV-1 microbicide development.

Authors:  Kabamba B Alexandre; Hazel T Mufhandu; Grace M London; E Chakauya; M Khati
Journal:  Virology       Date:  2016-07-16       Impact factor: 3.616

9.  The cytoplasmic domain of human immunodeficiency virus type 1 transmembrane protein gp41 harbors lipid raft association determinants.

Authors:  Polung Yang; Li-Shuang Ai; Shu-Chen Huang; Hsiao-Fen Li; Woan-Eng Chan; Chih-Wei Chang; Chiung-Yuan Ko; Steve S-L Chen
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

10.  Measuring the strength of interaction between the Ebola fusion peptide and lipid rafts: implications for membrane fusion and virus infection.

Authors:  Mônica S Freitas; Cristian Follmer; Lilian T Costa; Cecília Vilani; M Lucia Bianconi; Carlos Alberto Achete; Jerson L Silva
Journal:  PLoS One       Date:  2011-01-13       Impact factor: 3.240

View more
  18 in total

1.  Shedding-Resistant HIV-1 Envelope Glycoproteins Adopt Downstream Conformations That Remain Responsive to Conformation-Preferring Ligands.

Authors:  Maolin Lu; Xiaochu Ma; Nick Reichard; Daniel S Terry; James Arthos; Amos B Smith; Joseph G Sodroski; Scott C Blanchard; Walther Mothes
Journal:  J Virol       Date:  2020-08-17       Impact factor: 5.103

2.  Asymmetric Structures and Conformational Plasticity of the Uncleaved Full-Length Human Immunodeficiency Virus Envelope Glycoprotein Trimer.

Authors:  Shijian Zhang; Kunyu Wang; Wei Li Wang; Hanh T Nguyen; Shuobing Chen; Maolin Lu; Eden P Go; Haitao Ding; Robert T Steinbock; Heather Desaire; John C Kappes; Joseph Sodroski; Youdong Mao
Journal:  J Virol       Date:  2021-09-22       Impact factor: 5.103

3.  Global Increases in Human Immunodeficiency Virus Neutralization Sensitivity Due to Alterations in the Membrane-Proximal External Region of the Envelope Glycoprotein Can Be Minimized by Distant State 1-Stabilizing Changes.

Authors:  Qian Wang; Florian Esnault; Meiqing Zhao; Ta-Jung Chiu; Amos B Smith; Hanh T Nguyen; Joseph G Sodroski
Journal:  J Virol       Date:  2022-03-15       Impact factor: 6.549

4.  HIV envelope tail truncation confers resistance to SERINC5 restriction.

Authors:  Tafhima Haider; Xenia Snetkov; Clare Jolly
Journal:  Proc Natl Acad Sci U S A       Date:  2021-05-25       Impact factor: 12.779

5.  Cholesterol in the Viral Membrane is a Molecular Switch Governing HIV-1 Env Clustering.

Authors:  Jon Ander Nieto-Garai; Aroa Arboleya; Sara Otaegi; Jakub Chojnacki; Josefina Casas; Gemma Fabriàs; F-Xabier Contreras; Hans-Georg Kräusslich; Maier Lorizate
Journal:  Adv Sci (Weinh)       Date:  2020-12-21       Impact factor: 16.806

Review 6.  Membrane Heterogeneity Beyond the Plasma Membrane.

Authors:  Hong-Yin Wang; Deepti Bharti; Ilya Levental
Journal:  Front Cell Dev Biol       Date:  2020-11-19

Review 7.  HIV-1 Entry and Prospects for Protecting against Infection.

Authors:  Jean-François Bruxelle; Nino Trattnig; Marianne W Mureithi; Elise Landais; Ralph Pantophlet
Journal:  Microorganisms       Date:  2021-01-22

Review 8.  Membrane Interference Against HIV-1 by Intrinsic Antiviral Factors: The Case of IFITMs.

Authors:  Federico Marziali; Andrea Cimarelli
Journal:  Cells       Date:  2021-05-11       Impact factor: 6.600

Review 9.  Fluorescence Microscopy of the HIV-1 Envelope.

Authors:  Pablo Carravilla; José L Nieva; Christian Eggeling
Journal:  Viruses       Date:  2020-03-21       Impact factor: 5.048

10.  Potential Role of Oral Rinses Targeting the Viral Lipid Envelope in SARS-CoV-2 Infection.

Authors:  Valerie B O'Donnell; David Thomas; Richard Stanton; Jean-Yves Maillard; Robert C Murphy; Simon A Jones; Ian Humphreys; Michael J O Wakelam; Christopher Fegan; Matt P Wise; Albert Bosch; Syed A Sattar
Journal:  Function (Oxf)       Date:  2020-06-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.